European HTA

Since 2015, AMS has actively shaped the EU HTA process through regular contributions at conferences, participation in EUnetHTA events, and as a member of EUCOPE. Our practical experience and profound expertise gained during the development and compilation of rapid REA Submission Files during the EUnetHTA Joint Action 3 will ensure that you are well-prepared and guided through the EU HTA process.


Our services

  • Capability matching
    To ensure an efficient preparation of your relevant functions (Clinical Development, Regulatory Affairs, Market Access) for the EU HTA process, we will work together to develop an individualized playbook that can be further refined through dry runs.
  • Training
    We are happy to share our expertise through individually tailored workshops, presentations, and publications, equipping you for the EU HTA process.
  • Preparation of early consultations
    We support you in preparing briefing documents for European consultations (JSC), parallel consultations (EMA/HTA bodies), or national consultations, in order to anticipate the requirements of individual EU Member States in advance.
  • Anticipation of possible assessment scopes
    Considering different options for the assessment scope, we work together with you to create the corresponding value story for your product.
  • Comprehensive understanding of European HTA requirements
    We are here to offer guidance on evidence generation (such as study design, endpoints, subgroup or sensitivity analyses).
  • Scientific, strategic and methodological advice
    Together with you, we develop the data strategy and leverage visualization techniques to support and accelerate decision-making processes.
  • Development of a complete dossier
    We support you in deriving and presenting the patient numbers for Module 3 of the benefit dossier.
  • Parallel development of EU HTA and AMNOG dossiers
    With our experience in parallel procedures, we can also provide you with planning support throughout the national and EU HTA processes.


Do you have any questions? Our EU HTA team looks forward to hearing from you:


Transition from national to EU HTA: When will what be switched?

From January 2025, the Regulation on the European Health Technology Assessment will be implemented. The clinical domains of an HTA of newly authorised medicinal products will thereafter be prepared at European rather than national level: the EU HTA.  For various medicinal products, the benefit assessment at EU level JCA will become mandatory at different times. From 2030, JCAs will finally be mandatory for all medicines.Graphical representation of the timelines of the entry into force of the EU HTA.


Download: Flyer Timelines Entry into force of the EU HTA


Process of a JCA in the European benefit assessment

The JCA process is overseen by the Member State HTA Coordination Group. The JCA dossier is required 45 days prior to the CHMP Opinion and is published no later than 30 days after the marketing authorisation of the medicinal product by the EMA. A scoping process is carried out before the dossier is submitted. The results of this process form the research question and the scope of assessment for the dossier. The scoping process aims to define the PICOs (Population, Intervention, Comparator, Outcomes), which have the task of setting the framework for the evaluation and the data requirements for the manufacturer.

Ablauf europäischer NutzenbewertungenDownload: Flyer European benefit assessments


Publication List

Original articles in peer-reviewed journals

  • Schweitzer MK, Dold MN, Genet A, Gossens K, Klein-Hessling T, Löffler N, Rabel M, Rasch A, Reuter EM, Schmelcher J, Wolfram N, Werner S (2023). Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose. Eur J Health Econ. 2023 Oct 16. doi: 1007/s10198-023-01631-5
  • Schweitzer MK, Dold MN, Genet A, Gossens K, Klein-Hessling T, Löffler N, Rabel M, Rasch A, Schmelcher J, Werner S, Wolfram N (2023). Auswirkungen der neuen Dossieranforderungen Monitor Versorgungsforschung 03/23, p26–30, doi:
  • Genet A, Bogner K, Goertz R, Böhme S, Leverkus F (2023). Safety analysis of new medications in clinical trials: A simulation study to assess the differences between cause-specific and subdistribution frameworks in the presence of competing events. Research Square. doi: 21203/
  • Kisser A, Knieriemen J, Fasan A, Eberle K, Hogger S, Werner S, Taube T, Rasch A (2022). Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective. Eur J Health Econ 23(5):863-878, doi: 1007/s10198-021-01400-2
  • Wüstner S, Hogger S, Gartner-Freyer D, Lebioda A, Schley K, Leverkus F (2022). Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine. Front Public Health 18;10:804404, doi: 3389/fpubh.2022.804404
  • Schomaker M, Hogger S, Johnson LF, Hoffmann CJ, Bärnighausen T, Heumann C (2015). Simultaneous Treatment of Missing Data and Measurement Error in HIV Research Using Multiple Overimputation. Epidemiology. 26(5):628-36. doi: 1097/EDE.0000000000000334

Further publications (Workshops/Webinars/Presentations/Conference abstracts)

  • AMS (Eberle K), EUCOPE (2022) European HTA: What have we learned, what lies ahead?, Webinar, Information on EUCOPE website
  • AMS & Vfa (2021) New requirements for AMNOG-dossiers: Investigation of considered evaluations in the context of the benefit assessment by IQWiG and G-BA, Report, Information on Vfa website
  • Panni, T., Thiele, A., Carls A., Wallstab, A., Eberle, K. & Schleibner S (2018) PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA: AN EMPIRICAL APPROACH. Value in Health 21, p197-S8.
  • Rüther A, Herrmann K, Hebborn A, Perleth M, Schwarzer R, Schürmann C, et al. HTA und aktuelle Herausforderungen: Harmonisierung, Real World Data und Surrogatparameter. HTA – How to tackle pressing challenges: International Harmonization, Real World Data, and Surrogates. GMS Medizinische Informatik, Biometrie und Epidemiologie. 2018;Vol. 14(1).
  • Panni, T., Eberle, K., Seiler, N., Brüderl, M., Burkert-Kautzsch C, Carls A, et al. (2017) VP181 From National To European Assessment - The German Case. International Journal of Technology Assessment in Health Care, 33(S1), 234-5,
  • Hemmerling J, Eberle, K., Hogger S, Gupta M, Ullraum, A, & Seemüller S (2017) PP096 European Union-Health Technology Assessments For Medical Devices - How To Overcome Reimbursement Divergence. International Journal of Technology Assessment in Health Care, 33(S1), 116-117.
  • Gerlinde Jänel. Europäisches und nationales HTA – gleiches Ziel, gleiche Methodik? European and National – same aim, same method? HEC 2016: Health – Exploring Complexity. Joint Conference of GMDS, DGEpi, IEA-EEF, EFMI. München, 28.08.-02.09.2016. Düsseldorf: German Medical Science GMS Publishing House; 2016. DocAbstr. 876-2